2022
Long-term effects of increased adoption of artemisinin combination therapies in Burkina Faso
Zupko R, Nguyen T, Somé A, Tran T, Gerardin J, Dudas P, Giang D, Tran K, Wesolowski A, Ouédraogo J, Boni M. Long-term effects of increased adoption of artemisinin combination therapies in Burkina Faso. PLOS Global Public Health 2022, 2: e0000111. PMID: 36962300, PMCID: PMC10021447, DOI: 10.1371/journal.pgph.0000111.Peer-Reviewed Original ResearchMultiple first-line therapiesFirst-line therapyTreatment failure rateArtemether-lumefantrineFalciparum malariaCombination therapyLong-term effectsEqual long-term outcomesLower treatment failure rateUncomplicated Plasmodium falciparum malariaMajor global public health concernGlobal public health concernPlasmodium falciparum malariaP. falciparum malariaLong-term outcomesArtemisinin combination therapyP. falciparum transmissionPublic health concernMalaria settingsTreatment failureFailure rateHigh burdenTreatment efficacyACT useDrug resistance
2021
Persistent Submicroscopic Plasmodium falciparum Parasitemia 72 Hours after Treatment with Artemether-Lumefantrine Predicts 42-Day Treatment Failure in Mali and Burkina Faso
Beshir K, Diallo N, Somé F, Sombie S, Zongo I, Fofana B, Traore A, Dama S, Bamadio A, Traore O, Coulibaly S, Maurice O, Diarra A, Kaboré J, Kodio A, Togo A, Dara N, Coulibaly M, Dao F, Nikiema F, Compaore Y, Kabore N, Barry N, Soulama I, Sagara I, Sirima S, Ouédraogo J, Djimde A, Sutherland C. Persistent Submicroscopic Plasmodium falciparum Parasitemia 72 Hours after Treatment with Artemether-Lumefantrine Predicts 42-Day Treatment Failure in Mali and Burkina Faso. Antimicrobial Agents And Chemotherapy 2021, 65: 10.1128/aac.00873-21. PMID: 34060901, PMCID: PMC8284475, DOI: 10.1128/aac.00873-21.Peer-Reviewed Original ResearchConceptsArtemether-lumefantrineClinical episodesFirst treatment episodeComplete parasite clearanceDrug treatment groupPlasmodium falciparum parasitemiaQuantitative PCRMalaria transmission intensityEvaluable patientsParasitological efficacyParasite clearanceTreatment failureSubmicroscopic parasitemiaTreatment episodesTreatment outcomesTreatment groupsBetter efficacyDay 42Short intervalsH posttreatmentParasitemiaRegimensPatientsBurkina FasoTransmission intensity
2020
Efficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy change
Zongo I, Compaoré Y, Nikiéma F, Zongo M, Barry N, Somé F, Kaboré N, Ouédraogo J. Efficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy change. Pan African Medical Journal 2020, 35: 68. PMID: 32537072, PMCID: PMC7250195, DOI: 10.11604/pamj.2020.35.68.20849.Peer-Reviewed Original ResearchConceptsFirst-line therapyLine therapyUncomplicated malariaPolymerase chain reactionTreatment efficacyEarly treatment failureGood tolerability profileFirst-line treatmentParasitological responsePrimary endpointTolerability profileArtemether-lumefantrineTreatment failureLine treatmentASAQ groupDay 28Better efficacyBurkina FasoTherapyMalariaEfficacyChain reactionCompletion ratesTreatmentDaysIn vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso
Lingani M, Bonkian L, Yerbanga I, Kazienga A, Valéa I, Sorgho H, Ouédraogo J, Mens P, Schallig H, Ravinetto R, d’Alessandro U, Tinto H. In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso. Malaria Journal 2020, 19: 8. PMID: 31906948, PMCID: PMC6945612, DOI: 10.1186/s12936-019-3089-z.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAmodiaquineAntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsArtesunateBurkina FasoChildChild, PreschoolDrug CombinationsDrug Therapy, CombinationFemaleHumansInfantInhibitory Concentration 50LumefantrineMalaria, FalciparumMaleMass Drug AdministrationPlasmodium falciparumTreatment FailureTreatment OutcomeConceptsFirst-line treatmentArtemether-lumefantrineUncomplicated malariaFalciparum malariaTreatment failureOverall adverse event incidenceUncomplicated Plasmodium falciparum malariaEx vivo efficacyUnadjusted cure rateAdverse event incidenceUncomplicated falciparum malariaPlasmodium falciparum malariaP. falciparum susceptibilityMalaria-endemic areasEx vivo susceptibilityMass drug administrationP. falciparum isolatesEx vivo analysisAL armASAQ armOpen labelPrimary endpointRecurrent parasitaemiaEvent incidenceTreatment arms
2017
TO VALUE THE EFFICIENCY OF PYRONARIDINE-ARTESUNATE AND ARTEMETHER-LUMEFANTRINE IN THE TREATMENT OF UNCOMPLICATED MALARIA OF PLASMODIUM SPP. IN BURKINA FASO
Barry N, Kaboré N, Kabré Z, Fofana A, Nikèma F, Compaoré D, Somé F, Zongo I, Djimdé A, Ouédraogo J. TO VALUE THE EFFICIENCY OF PYRONARIDINE-ARTESUNATE AND ARTEMETHER-LUMEFANTRINE IN THE TREATMENT OF UNCOMPLICATED MALARIA OF PLASMODIUM SPP. IN BURKINA FASO. BMJ Global Health 2017, 2: a24. DOI: 10.1136/bmjgh-2016-000260.62.Peer-Reviewed Original ResearchArtemether-lumefantrineUncomplicated malariaTreatment failurePA groupAL groupEffective malaria vaccineStandard of careNew therapeutic drugsPyronaridine-ArtesunateMalaria vaccinePatient groupTherapeutic failureFirst episodeTreatment responseDay 28Malaria diagnosisDay 42Burkina FasoMalaria controlEvidence baseLess casesPlasmodium sppTherapeutic drugsMalariaBobo-Dioulasso
2016
Artesunate-Amodiaquine and Artemether-Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso
Sondo P, Derra K, Nakanabo S, Tarnagda Z, Kazienga A, Zampa O, Valéa I, Sorgho H, Owusu-Dabo E, Ouédraogo J, Guiguemdé T, Tinto H. Artesunate-Amodiaquine and Artemether-Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso. PLOS ONE 2016, 11: e0151565. PMID: 27031231, PMCID: PMC4816516, DOI: 10.1371/journal.pone.0151565.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAllelesAmodiaquineAntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsBurkina FasoChildDrug CombinationsEthanolaminesFemaleFluorenesGene FrequencyGenotypeHost-Parasite InteractionsHumansMalaria, FalciparumMaleMembrane Transport ProteinsMiddle AgedMultidrug Resistance-Associated ProteinsMultivariate AnalysisParasitemiaPlasmodium falciparumPolymorphism, Single NucleotideProtozoan ProteinsTreatment OutcomeConceptsPfmdr1 allelesTreatment failureArtemether-lumefantrine therapyPfcrt K76TSingle nucleotide polymorphismsRestriction fragment length polymorphism methodFragment length polymorphism methodPotential beneficial effectsLength polymorphism methodArtesunate-AmodiaquineRecurrent parasitaemiaTreatment regimenACT resistanceCombination therapyK76TPfmdr1 geneClinical trialsTreatment outcomesMultivariate analysisDay 0PfcrtMalaria controlBlood spotsBeneficial effectsPolymorphism methodLessons learnt from 20 years surveillance of malaria drug resistance prior to the policy change in Burkina Faso.
Tinto H, Valea I, Ouédraogo J, Guiguemdé T. Lessons learnt from 20 years surveillance of malaria drug resistance prior to the policy change in Burkina Faso. Annals Of Parasitology 2016, 62: 17-24. PMID: 27262953, DOI: 10.17420/ap6201.27.Peer-Reviewed Original ResearchConceptsDrug resistanceChloroquine resistanceYear surveillanceSeasonal malaria chemoprophylaxisIntermittent preventive treatmentMalaria drug resistanceSulfadoxine-pyrimethamine resistanceSystematic surveillance systemGood surveillance systemSurveillance systemLate recrudescenceMalaria chemoprophylaxisUncomplicated malariaSulfadoxine-pyrimethamineTreatment failurePregnant womenCombination therapyDevelopment of resistancePreventive treatmentReal prevalenceTreatment resistanceLow prevalenceSentinel sitesAntimalarial drugsBurkina Faso
2007
Randomized Comparison of Amodiaquine plus Sulfadoxine-Pyrimethamine, Artemether-Lumefantrine, and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Burkina Faso
Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Séré Y, Rosenthal P, Ouédraogo J. Randomized Comparison of Amodiaquine plus Sulfadoxine-Pyrimethamine, Artemether-Lumefantrine, and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Burkina Faso. Clinical Infectious Diseases 2007, 45: 1453-1461. PMID: 17990228, DOI: 10.1086/522985.Peer-Reviewed Original ResearchConceptsUncomplicated Plasmodium falciparum malariaPlasmodium falciparum malariaFalciparum malariaArtemether-lumefantrineRecurrent parasitemiaUncomplicated P. falciparum malariaCombination antimalarial therapyEarly treatment failureSerious adverse eventsP. falciparum malariaDrug-resistant parasitesYears of ageMonths of ageAntimalarial regimenDihydroartemisinin-PiperaquineLumefantrine regimenAdverse eventsCombination regimensSulfadoxine-pyrimethamineRandomized comparisonTreatment failureNew regimenRecurrent malariaAntimalarial therapyTreatment groupsSulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women.
Tinto H, Ouédraogo J, Zongo I, van Overmeir C, van Marck E, Guiguemdé T, D'Alessandro U. Sulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women. American Journal Of Tropical Medicine And Hygiene 2007, 76: 608-13. PMID: 17426157, DOI: 10.4269/ajtmh.2007.76.608.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAnimalsAntimalarialsBurkina FasoChildChild, PreschoolChloroquineDrug Administration ScheduleDrug CombinationsDrug ResistanceFemaleGenotypeHumansInfantMalaria, FalciparumMaleMutationPlasmodium falciparumPregnancyPregnancy Complications, ParasiticPyrimethamineSelection, GeneticSulfadoxineTetrahydrofolate DehydrogenaseConceptsSulfadoxine-pyrimethamine efficacyTriple dhfr mutationDHFR mutationsRecurrent parasitemiaIntermittent preventive treatmentSulfadoxine-pyrimethamine resistanceYears of ageSuch high prevalenceDihydropteroate synthetase (Pfdhps) mutationsPCR-restriction fragment length polymorphismSulfadoxine-pyrimethamineTreatment failurePregnant womenPolymerase chain reactionPreventive treatmentHigh prevalenceNew infectionsChain reactionMutant parasitesPatientsParasitemiaTreatmentFragment length polymorphismPrevalenceEfficacyArtemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial
Zongo I, Dorsey G, Rouamba N, Tinto H, Dokomajilar C, Guiguemde R, Rosenthal P, Ouedraogo J. Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. The Lancet 2007, 369: 491-498. PMID: 17292769, DOI: 10.1016/s0140-6736(07)60236-0.Peer-Reviewed Original ResearchConceptsUncomplicated falciparum malariaTreatment failureUncomplicated malariaArtemether-lumefantrineRecurrent parasitaemiaFalciparum malariaNew infectionsArtemisinin-based combination treatmentLate treatment failureEarly treatment failureNon-inferiority trialSymptomatic malariaEffective regimensPrimary endpointCombination regimensStandard dosesAvailable regimenCombination treatmentDrug susceptibilityPatientsAmodiaquineMalarial treatmentMalariaRegimensBobo-Dioulasso
2006
In vivo sensitivity of Plasmodium faciparum to chloroquine and sulfadoxine pyrimethamine in the Bobo Dioulasso region (1998-2001): risk factors associated with treatments failures to the two drugs.
Tinto H, Sanou B, Erhart A, D'Alessandro U, Ouédraogo J, Guiguemdé T. In vivo sensitivity of Plasmodium faciparum to chloroquine and sulfadoxine pyrimethamine in the Bobo Dioulasso region (1998-2001): risk factors associated with treatments failures to the two drugs. Bulletin De La Société De Pathologie Exotique 2006, 99: 161-5. PMID: 16983817.Peer-Reviewed Original ResearchConceptsCQ treatment failureTreatment failureRisk factorsMultivariate analysisVivo field testTotal treatment failureYears of ageTime of recruitmentSignificant increaseSulfadoxine-pyrimethamineCQ groupUnivariate analysisHealth centersAge of childrenLate failureLow parasitaemiaBetter efficacyDay 14Therapeutic efficacyDay 0SP groupVivo sensitivityParasitaemiaChloroquineDrugs
2005
Amodiaquine, sulfadoxine-pyrimethamine, and combination therapy for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso.
Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Lankoande M, Ouedraogo J, ROSENTHAL P. Amodiaquine, sulfadoxine-pyrimethamine, and combination therapy for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. American Journal Of Tropical Medicine And Hygiene 2005, 73: 826-32. PMID: 16282288, DOI: 10.4269/ajtmh.2005.73.826.Peer-Reviewed Original ResearchConceptsUncomplicated falciparum malariaFalciparum malariaTreatment failureEfficacy of amodiaquineEarly treatment failureSerious adverse eventsPatients 6 monthsRisk of recrudescenceEfficacy outcomesUncomplicated malariaAdverse eventsWHO criteriaAvailable therapiesCombination therapyAntimalarial therapyClinical failureNew infectionsAmodiaquineBurkina FasoTherapyRelative efficacyMalariaBobo-DioulassoPyrimethamineTrialsUsefulness of the Plasmodium falciparum chloroquine resistance transporter T76 genotype failure index for the estimation of in vivo chloroquine resistance in Burkina Faso.
Tinto H, Sanou B, Dujardin J, Ouédraogo J, VAN Overmeir C, Erhart A, VAN Marck E, Guiguemdé T, D'Alessandro U. Usefulness of the Plasmodium falciparum chloroquine resistance transporter T76 genotype failure index for the estimation of in vivo chloroquine resistance in Burkina Faso. American Journal Of Tropical Medicine And Hygiene 2005, 73: 171-3. PMID: 16014853, DOI: 10.4269/ajtmh.2005.73.171.Peer-Reviewed Original Research